The manufacturer recorded a net profit of RON23.1 million in the first half, up 20% compared with the first half of 2021.
After the health crisis led to a decrease in the consumption of medicines in hospitals – one of the segments where Antibiotice has a strong presence, the lifting of restrictions led to an increase in presentations in medical facilities, and therefore in sales of medicines.
The company also bet heavily on exports in the first half of 2022, which went up to RON95.3 million, almost 40% compared with the same period last year. In fact, about 38% of Antibiotice’s sales in the first half of the year came from exports, according to ZF calculations.
(English version by Loredana Fratila-Cristescu)